A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
Ontology highlight
ABSTRACT: This is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides]) as adjuvant treatment of minimal residual disease (MRD) in subjects with KRAS/neuroblastoma ras viral oncogene homolog (NRAS) mutated PDAC or other solid tumors.
DISEASE(S): Adenocarcinoma,Kras G12r,Gallbladder Carcinoma,Minimal Residual Disease,Colorectal Cancer,Nras G12r,Pancreatic Ductal Adenocarcinoma,Neoplasm, Residual,Ovarian Cancer,Kras G12d,Colon Cancer,Bile Duct Neoplasms,Non-small Cell Lung Cancer,Bile Duct Cancer,Colorectal Neoplasms,Carcinoma, Non-small-cell Lung,Ovarian Neoplasms,Nras G12d,Cholangiocarcinoma
PROVIDER: 2374931 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA